Simon et al reviewed the skeletal consequences of discontinuing HT and the specific treatment options for these women. [12] This analysis included 11 RCTs that reported data on BMD changes during and ...

Nonsteroidal anti-inflammatory drugs (NSAIDs) seemed to neutralize the protective benefit of a certain bisphosphonate, according to a post-hoc analysis of a randomized controlled trial. Among over ...

Please provide your email address to receive an email when new articles are posted on . Despite potential side effects, bisphosphonate therapy may benefit postmenopausal women with osteoporosis by ...

About a year was determined to be the minimal timing of bisphosphonate therapy for postmenopausal women with osteoporosis to reap a benefit, according to a meta-analysis. Looking at 10 randomized ...

The FDA analyses looked at a composite end point of all fractures, both vertebral and nonvertebral, and showed little benefit of continued bisphosphonate treatment beyond 5 years. The original ...

Studies show conflicting results regarding the possible excess risk of atypical fractures of the femoral shaft associated with bisphosphonate use. In Sweden, 12,777 women 55 years of age or older ...

January 8, 2008 — Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug Administration ...

Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations We conducted a retrospective ...

Please provide your email address to receive an email when new articles are posted on . Strauss and colleagues analyzed data from two primary-care electronic record databases, the U.K. Clinical ...

Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: ...